Hunan Warrant Pharmaceutical's (SHA:688799) investee company, Shanghai Zhigen Pharmaceutical Technology, completed the phase I trials of ZG-002 tablets, according to a Shanghai bourse filing on Friday.
The drug was developed to treat moderate-to-severe plaque psoriasis.
The clinical trial showed that the drug is safe to use and was well tolerated by patients.
The pharmaceutical company's shares rose 1% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.